You can follow the discussion on âIn Surprise Decision, FDA Blocks Crucial Cognitive Claim for Takeda's Brintellixâ without having to leave a comment. Cool, huh? Just enter your email address in the form here below and you're all set.
© 2024 Mad in America Foundation